| |MAY 20249US FDA NODS X4 PHARMACEUTICAL'S THERAPY FOR IMMUNODEFICIENCY DISEASEAMERICAN ONCOLOGY INSTITUTE (AOI) IN MANGALAGIRI PIONEERS INNOVATIVE APPROACH IN BREAST CANCER SURGERY FOR HIGH-RISK PATIENTSAmerican Oncology Institute (AOI) in Mangalagiri proudly announces a groundbreaking advancement in the treatment of breast cancer. Recently, AOI successfully treated three high-risk patients with carcinoma breast using a novel anaesthetic technique, marking a significant milestone in cancer care.Dr. Kalyan Polavarapu, Surigical Oncologist, at AOI, commented, Treating patients with breast cancer who also suffer from significant comorbidities presents a unique set of challenges. Our goal is to provide the best possible care while minimizing risks and ensuring patient safety.The treated patients included V.L (67 years), J.B (74 years), and P.S (83 years), all considered very high risk for general anaesthesia due to their existing comorbidities. Despite these challenges, all three patients underwent MRM surgery without complications and were discharged within three days post-operation.Dr. Sreedevi, Consultant anesthesiologist, at AOI, commented, Paravertebral block (with ultrasound guidance ) involves administering a local anaesthetic near the spinal nerves, resulting in somatic and sympathetic nerve blockade. This technique boasts a low incidence of adverse effects, making it a safe and effective alternative for high-risk patients. By implementing Paravertebral and PECS blocks, we were able to tailor the anaesthetic approach to each patient's individual needs, resulting in successful surgical outcomes.Mahendra Reddy, Regional Chief Operating Officer (RCOO) of AOI, Vijayawada, expressed his pride in the hospital's achievement, stating, "At AOI, we are committed to pushing the boundaries of cancer care and delivering innovative solutions to improve patient outcomes. The successful treatment of these high-risk breast cancer patients underscores our dedication to excellence and reinforces our position as a leader in oncology care." POThe US FDA has approved its treatment for patients over 12 with a rare genetic immunodeficiency disease, per X4 Pharmaceuticals. X4's mavorixafor, to be sold under the brand name Xolremdi, is the primary treatment to get U.S. endorsement explicitly for treating WHIM syndrome.WHIM is described by disorders in which the body's resistant framework doesn't work as expected. It is an abbreviation for warts, hypogammaglobulinemia or low immunizer levels, contaminations, and myelokathexis or low white platelet count, which are side effects of the problem.The biotechnology firm has established an annual wholesale acquisition cost of $496,400 for patients weighing more than 50 kilograms and $372,300 for patients weighing less than or equal to 50 kilograms for Xolremdi. The endorsement depends on a late-stage review showing that the treatment showed a 60 percent decrease in disease rate compared to placebo when tried in patients with WHIM syndrome.Xolremdi works by targeting the CXCR4 gene in the body. This gene helps white blood cells move from the bone marrow into the blood, which makes the immune system work better. The treatment is likewise being assessed for different signs, including specific constant problems where the body has low levels of a kind of white blood cell called neutrophils. PO
< Page 8 | Page 10 >